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Active surveillance (AS) is an accepted option for the 
initial management of carefully selected men with local-
ized, well-differentiated prostate cancer who are thought 
to have a low risk of progression1–4. AS is broadly 
described as a management option for patients with 
low-risk prostate cancer, which involves the postpone-
ment or avoidance of invasive treatment, with a switch 
to curative treatment if evidence is obtained that the 
patient has an increased risk of disease progression or if 
the patient expresses preference for it. However, seman-
tic heterogeneity exists in the literature and guidelines. 
For instance, the specific definitions of the terms AS and 
watchful waiting (WW) are inconsistent in the published 
literature and can elicit considerable confusion. The 
terms AS and WW are frequently used interchangeably, 
but they refer to very different observational approaches. 
AS involves the avoidance or postponement of immedi-
ate therapy combined with careful surveillance; defini-
tive treatment is then offered if there is evidence that 
the patient is at increased risk of disease progression4. 
AS differs from WW, which is based upon the prem-
ise that men will not benefit from definitive treatment 
of clinically localized prostate cancer owing to limited 
life expectancy, comorbidity, and the prolonged natural 
history of the prostate cancer4. Patients managed using a 
WW protocol undergo observation consisting of a lesser 
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Abstract | Active surveillance (AS) is broadly described as a management option for men with 
low-risk prostate cancer, but semantic heterogeneity exists in both the literature and in 
guidelines. To address this issue, a panel of leading prostate cancer specialists in the field of AS 
participated in a consensus-forming project using a modified Delphi method to reach 
international consensus on definitions of terms related to this management option. An iterative 
three-round sequence of online questionnaires designed to address 61 individual items was 
completed by each panel member. Consensus was considered to be reached if ≥70% of the 
experts agreed on a definition. To facilitate a common understanding among all experts 
involved and resolve potential ambiguities, a face-to-face consensus meeting was held between 
Delphi survey rounds two and three. Convenience sampling was used to construct the panel of 
experts. In total, 12 experts from Australia, France, Finland, Italy, the Netherlands, Japan, the UK, 
Canada and the USA participated. By the end of the Delphi process, formal consensus was 
achieved for 100% (n = 61) of the terms and a glossary was then developed. Agreement between 
international experts has been reached on relevant terms and subsequent definitions regarding 
AS for patients with localized prostate cancer. This standard terminology could support 
multidisciplinary communication, reduce the extent of variations in clinical practice and 
optimize clinical decision making.
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degree of monitoring than those on AS might receive, 
and in which palliative treatment is generally instituted 
if metastases or local symptoms develop. Interpreting 
and comparing research results is difficult owing to the 
nonstandardized use of the terms AS and WW and their 
intended and often mixed treatment objectives (curative 
or palliative)5.
This semantic heterogeneity is also reflected in AS 
guidelines6. In these guidelines, AS is primarily recom-
mended for patients with low-risk tumours; however, 
these guidelines contain various definitions of low-risk 
prostate cancer, as specified by different combinations 
of clinical criteria including clinical and pathological 
characteristics (such as tumour stage, serum PSA levels, 
biopsy Gleason score, tumour volume and serum PSA 
density). Furthermore, definitions of disease reclassifica-
tion and progression differ among published guidelines 
and multiple criteria for initiation of curative treatment 
are proposed6.
Problems resulting from the use of ambiguous lan-
guage include hindered clinical decision making, par-
ticularly in multidisciplinary collaborations, and limited 
opportunities for research7. Moreover, such ambiguity 
has raised a barrier that hampers exchange of knowledge 
within and between fundamental domains of research 
and research groups8. An urgent need exists for uni-
form terminology to help clarify scientific discourse: 
that is, we need to speak the same language. The pri-
mary purpose of this study was to reach international 
consensus on definitions of terms that are often used in 
AS undertaken for carefully selected men with localized, 
 well-differentiated prostate cancer.
Methods used to develop definitions
Expert panel. Convenience sampling was used to con-
struct the panel of experts. The Movember Foundation’s 
Global Action Plan Active Surveillance (GAP3) project 
is an integrated project lasting 30 months that is being 
implemented across 14 countries in the five Movember 
regions (Australasia, Europe, the UK, Canada, the 
USA)9. Milestones of the project include the develop-
ment of a global AS database for clinical, biospecimen, 
imaging and biomarker data, worldwide, tailor-made 
guidelines on AS and a web-based AS platform for 
patients and providers. The experts for the panel were 
selected within the Movember Foundation’s GAP3 
consortium (BOX 1), consisting of urologists, acclaimed 
scientists, a pathologist and radiation oncologists with 
expertise in the field of AS. We aimed at including at 
least one expert per participating institute (currently, 
n = 15) in the GAP3 consortium. Eligible experts were 
invited by e-mail to participate in the study. After par-
ticipating, the experts were asked to provide personal 
information, such as their specialty8.
List of terms. As part of the GAP3 initiative, a narrative 
review of available AS guidelines provided a compre-
hensive overview of recommendations regarding patient 
selection, frequency and type of monitoring and the cri-
teria for initiation of definitive treatment6. This review 
has been used as a starting point to produce a list of 
potentially important terms (led by Sophie Bruinsma, a 
researcher in the field of prostate cancer). Subsequently, 
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Key points
• Active surveillance (AS) is broadly described as a management option for men with 
low-risk prostate cancer, but semantic heterogeneity exists in the literature and 
guidelines
• An urgent need for uniform terminology exists to establish active communication and 
collaboration between research groups around the world
• Agreement between international experts has been reached on 61 relevant terms and 
subsequent definitions regarding AS for patients with localized prostate cancer
• This standard terminology could support multidisciplinary communication, reduce 
the extent of variation in clinical practice and optimize clinical decision making
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Box 1 | Members of the Movember Foundation’s GAP3 consortium
Principle Investigators
Bruce Trock (Johns Hopkins University, The James Buchanan Brady Urological Institute, Baltimore, USA), Behfar Ehdaie 
(Memorial Sloan Kettering Cancer Center, New York, USA), Peter Carroll (University of California San Francisco, 
San Francisco, USA), Christopher Filson (Emory University School of Medicine, Winship Cancer Institute, Atlanta, USA), 
Jeri Kim (MD Anderson Cancer Center, Houston, USA), Todd Morgan (University of Michigan and Michigan Urological 
Surgery Improvement Collaborative, Michigan, USA), Laurence Klotz (University of Toronto, Sunnybrook Health Sciences 
Centre, Toronto, Ontario, Canada), Tom Pickles (University of British Columbia, BC Cancer Agency, Vancouver, Canada), 
Eric Hyndman (University of Calgary, Southern Alberta Institute of Urology, Calgary, Canada), Caroline M. Moore 
(University College London and University College London Hospital Trust, London, UK), Vincent Gnanapragasam 
(University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK), Mieke Van 
Hemelrijck (King’s College London, London, UK & Guy’s and St Thomas’ NHS Foundation Trust, London, UK), Prokar 
Dasgupta (Guy’s and St Thomas’ NHS Foundation Trust, London, UK), Chris Bangma (Erasmus Medical Center, Rotterdam, 
Netherlands), Monique Roobol (Erasmus Medical Center, Rotterdam, Netherlands), Arnauld Villers (Lille University 
Hospital Center, Lille, France), Antti Rannikko (Helsinki University and Helsinki University Hospital, Helsinki, Finland), 
Riccardo Valdagni (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy), Antoinette Perry (University 
College Dublin, Dublin, Ireland), Jonas Hugosson (Sahlgrenska University Hospital, Göteborg, Sweden), Jose 
Rubio-Briones (Instituto Valenciano de Oncología, Valencia, Spain), Anders Bjartell (Skåne University Hospital, Malmö, 
Sweden), Lukas Hefermehl (Kantonsspital Baden, Baden, Switzerland), Lee Lui Shiong (Singapore General Hospital, 
Singapore, Singapore), Mark Frydenberg (Monash Health; Monash University, Melbourne, Australia), Yoshiyuki Kakehi 
(Kagawa University Faculty of Medicine, Kagawa, Japan), Byung Ha Chung (Gangnam Severance Hospital, Yonsei 
University Health System, Seoul, Republic of Korea), Kwang Suk Lee (Gangnam Severance Hospital, Yonsei University 
Health System, Seoul, Republic of Korea).
Pathologist
Theo van der Kwast (Princess Margaret Cancer Centre, Toronto, Canada).
Technology Research Partners
Henk Obbink (Royal Philips, Eindhoven, Netherlands), Wim van der Linden (Royal Philips, Eindhoven, Netherlands), 
Tim Hulsen (Royal Philips, Eindhoven, Netherlands), Cees de Jonge (Royal Philips, Eindhoven, Netherlands).
Regional statisticians
Mike Kattan (Cleveland Clinic, Cleveland, Ohio, USA), Ji Xinge (Cleveland Clinic, Cleveland, Ohio, USA), Kenneth Muir 
(University of Manchester, Manchester, UK), Artitaya Lophatananon (University of Manchester, Manchester, UK), 
Michael Fahey (Epworth HealthCare, Melbourne, Australia), Ewout Steyerberg (Erasmus Medical Center, Rotterdam, 
Netherlands), Daan Nieboer (Erasmus Medical Center, Rotterdam, Netherlands); Liying Zhang (University of Toronto, 
Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada)
Clinical Research Partners’ IT Experts
Wei Guo (Johns Hopkins University, The James Buchanan Brady Urological Institute, Baltimore, USA), Tanya Milan 
(Memorial Sloan Kettering Cancer Center, New York, USA), Nicole Benfante (Memorial Sloan Kettering Cancer Center, 
New York, USA), Janet Cowan (University of California San Francisco, San Francisco, USA), Dattatraya Patil (Emory 
University School of Medicine, Winship Cancer Institute, Atlanta, USA), Rachel Sanford (MD Anderson Cancer Center, 
Houston, USA), Tae-Kyung Kim (University of Michigan and Michigan Urological Surgery Improvement Collaborative, 
Ann Arbor, Michigan, USA), Alexandre Mamedov (University of Toronto, Sunnybrook Health Sciences Centre, Toronto, 
Canada), Vincent LaPointe (University of British Columbia, BC Cancer Agency, Vancouver, Canada), Trafford Crump 
(University of Calgary, Southern Alberta Institute of Urology, Calgary, Canada), Rifat Hamoudi (University College London 
and University College London Hospital Trust, London, UK), Jenna Kimberly-Duffell (University of Cambridge and 
Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK), Aida Santaolalla (King’s College London, 
London, UK and Guy’s and St Thomas’ NHS Foundation Trust, London, UK), Daan Nieboer (Erasmus Medical Center, 
Rotterdam, Netherlands), Jonathan Olivier (Lille University Hospital Center, Lille, France), Emanuele Bianchi Janetti 
(Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy), Tiziana Rancati (Fondazione IRCCS Istituto 
Nazionale dei Tumori di Milano, Milan, Italy), Helén Ahlgren (Sahlgrenska University Hospital, Göteborg, Sweden), Juanma 
Mascarós (Instituto Valenciano de Oncología, Valencia, Spain), Annica Löfgren (Skåne University Hospital, Malmö, 
Sweden), Kurt Lehmann (Kantonsspital Baden, Baden, Switzerland), Catherine Han Lin (Monash University and Epworth 
HealthCare, Melbourne, Australia), Hiromi Hirama (Kagawa University, Kagawa, Japan).
Research Advisory Committee
Guido Jenster (Erasmus MC, Rotterdam, Netherlands), Anssi Auvinen (University of Tampere, Tampere, Finland), 
Anders Bjartell (Skåne University Hospital, Malmö, Sweden), Masoom Haider (University of Toronto, Toronto, Canada), 
Kees van Bochove (The Hyve B.V. Utrecht, Utrecht, Netherlands), Ballentine Carter (Johns Hopkins University, 
Baltimore, USA).
Management team
Rachelle Kirk-Burnnand (Movember Foundation, Melbourne, Australia), Sam Gledhill (Movember Foundation, Melbourne, 
Australia), Mark Buzza (Movember Foundation, Melbourne, Australia), Sophie Bruinsma (Erasmus Medical Center, 
Rotterdam, Netherlands).
GAP3; Global Action Plan Prostate Cancer Active Surveillance.
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this list has been critically reviewed by Monique J. Roobol 
(an epidemiologist) and Chris H. Bangma (a urologist), 
from Erasmus MC, the Netherlands, who are experts 
in the field of prostate cancer, and items were added if 
considered needed. In total, the initial list addressed 53 
individual items.
Procedure for determining definitions
Consensus definitions were derived using a Delphi 
method. The Delphi method is a widely accepted tech-
nique of structured and systematic information gather-
ing from a group of experts (termed the Delphi Panel) 
on a specific topic using a series of questionnaires10. The 
Delphi method enables a panel of experts to provide 
insights and opinions, even when they are not located 
in the same geographic area. According to this formal 
consensus-building method, participants were asked 
to fill out an iterative sequence of surveys, in this case 
in the form of online questionnaires. The current study 
uses a modified Delphi method, in which online surveys 
were combined with a physical meeting of the panel of 
experts (FIG. 1).
In the first round, the experts were asked to provide 
definitions of 53 terms related to AS for low-risk pros-
tate cancer according to their personal opinion. These 
experts were informed that this list might not be exhaus-
tive and were asked to add potentially missing items and 
their corresponding definitions to the list at the end of 
the survey. The open comments made by the experts 
were carefully considered by the referee group8, consist-
ing of Bruinsma and Roobol, and, based on the input 
of the experts, temporary definitions were formulated 
and clustered into themes. These temporary definitions 
were presented to the experts in a second-round survey 
and they were asked whether they agreed or disagreed 
with the proposed definitions; if they did not agree with 
a certain definition, the experts were asked to clearly 
state why. Consistent with other studies11–13, consensus 
was considered to be reached if ≥70% of the experts 
agreed on a definition8. If consensus was achieved on 
definitions, these were added to the AS dictionary or 
glossary of terms (hereafter, referred to as the glossary) 
(TABLE 1). Subsequently, to facilitate a common under-
standing among all experts involved and to resolve 
potential ambiguities, a consensus, in-person meeting 
was held, which was attended by representatives from 
the majority of the countries participating in the GAP3 
consortium (the third round). This meeting was organ-
ized in conjunction with the annual conference of the 
European Association of Urology (EAU) in March 2016, 
hosted in Munich (Germany). During this meeting, the 
majority of the terms and subsequent definitions on 
which no consensus had been reached in the previous 
surveys were further discussed by the experts. Based on 
the second survey and the input of the experts during the 
face-to-face consensus meeting, a third and final survey 
was designed (the fourth round). This final survey con-
sisted of: terms and subsequent definitions on which no 
consensus had been reached in the second survey, and 
were adapted based on the input of the experts from this 
survey; terms and subsequent definitions on which no 
consensus was reached in the second survey, that were 
discussed during the consensus meeting, and subse-
quently adapted based on the experts’ input at the con-
sensus meeting; and terms and subsequent definitions 
on which consensus was reached in the second survey, 
but were adapted based on suggestions for improve-
ment from the experts in the second survey. We asked 
the experts whether they agreed or disagreed with the 
formulated consensus definitions. If they did not agree 
with a certain definition, the experts were asked to 
clearly state why they did not agree with the proposed 
definition. Consensus was considered to be reached if 
≥70% of the experts agreed on a definition. Consensus 
definitions were added to the glossary (TABLE 1).
Survey administration. Three rounds of surveys were 
conducted between January 2016 and April 2016. The 
experts were given ~2 weeks to complete each sur-
vey round, and several reminder e-mails were sent. In 
the first round, the preliminary survey was sent to all 
experts. The second-round survey was only sent to the 
responders from the initial round. All experts who 
responded to the first and second survey were permitted 
to participate in the consensus meeting (third round). 
The third and final survey (round four) was dissemi-
nated to all participants from round two and to those 
present at the consensus meeting who did not  participate 
in round two.
Nature Reviews | Urology
Expert consensus deﬁnitions (AS dictionary or glossary of terms)
Final consensus analysis
Round 4: Online survey
Round 3: (Face-to-face) consensus meeting
Round 2: Online survey
Round 1: Online survey
Selection of experts
Item generation (development survey) 
Systematic review
Deﬁnition of problem
Figure 1 | Key elements of the proposed modified 
Delphi study. The Delphi method is a widely accepted 
technique of structured and systematic information 
gathering from a group of experts (termed the Delphi 
Panel) on a specific topic using a series of questionnaires. 
The Delphi method enables a panel of experts to provide 
insights and opinions, even when they are not located in 
the same geographic area. The current study uses a 
modified Delphi method, in which an iterative sequence 
of online surveys were combined with a physical 
meeting of the panel of experts
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Table 1 | Glossary of terms related to active surveillance
Term Definition % of 
agreement
Background
Overdetection The detection of cancers that would not have been discovered in the absence of screening (such as 
PSA), and would not have caused any (clinical) problems
100
Overdiagnosis The diagnosis of a clinically insignificant cancer that would not have been discovered in the absence of 
screening (such as PSA), and that would not harm the patient
100
Overtreatment The treatment of clinically insignificant cancer that would otherwise not have harmed the patient 
during his lifetime
100
Risk groups and surveillance
Risk The likelihood of a defined event 100
Risk group A system classifying patients into categories sharing approximately the same likelihood of a defined 
event (such as risk), based on clinical and pathological findings (including tumour stage, serum PSA 
levels and biopsy Gleason score)
100
(Clinical) risk stratification The process of assigning patients with prostate cancer to risk groups based on clinical features (such as 
PSA level, DRE and biopsy findings)
100
Very-low-risk prostate cancer Prostate cancer with a minimal risk of progression on repeat biopsy (such as an increase in Gleason 
score or an increased number of cores positive for cancer) and with very good prognosis
75
Low-risk prostate cancer Prostate cancer with a low risk of progression on repeat biopsy (such as an increase in Gleason score 
or an increased number of cores positive for cancer) and with a good prognosis
75
Intermediate-risk prostate cancer Prostate cancer with a moderate risk of progression on repeat biopsy (such as an increase in Gleason 
score or an increased number of cores positive for cancer) and with a reasonable prognosis
83
High-risk prostate cancer Prostate cancer with a high risk of metastasis or cancer-specific death if left untreated 92
Cancer definitions
Localized prostate cancer Cancer that is confined within the prostate (for example, not spread outside the prostate), classified by 
clinical stage <T3
100
Indolent tumour A tumour that is slow growing, or not growing at all. 75
Early prostate cancer Small-volume, localized prostate cancer 100
Clinically insignificant prostate 
cancer
Prostate cancer that is, despite the absence of treatment, unlikely to cause symptoms, or metastasize 
(even in the absence of symptoms) or to cause mortality during a man’s lifetime
100
Favourable-risk disease A low-risk prostate cancer, characterized by T1(c) or T2, PSA<10 ng/mL and biopsy Gleason score of ≤6 90
Biopsy
Protocol-based biopsy A biopsy scheduled as part of a predefined AS protocol 100
Non-protocol-based biopsy A biopsy outside the predefined AS protocol 90
Diagnostic biopsy The first biopsy is positive for prostate cancer 100
Confirmatory biopsy The prostate biopsy following a positive diagnostic biopsy (such as the first biopsy positive for prostate 
cancer) that is intended to confirm clinical insignificance of the previously diagnosed prostate cancer, 
is typically performed within 12 months after diagnosis and might target previously undersampled 
areas, according to a protocol that specifies minimum standards
92
Targeted biopsy Sampling of specific areas of the prostate that are suspicious for cancer, usually based on DRE or 
imaging findings
100
MR-targeted biopsy Any biopsy technique (such as cognitive, fusion, in-bore) in which an MRI scan is used to determine the 
location of a suspicious target prior to biopsy
100
Treatment choice
Active surveillance A monitoring strategy for patients with prostate cancer with the aim of avoiding or deferring curative 
treatment
100
Watchful waiting Management of patients with a limited life expectancy, in whom palliative treatment (without curative 
intent) is initiated if symptoms develop
100
Definitive treatment Any treatment with curative intent 80
Active treatment Treatment (such as surgery, radiotherapy or focal therapy) for prostate cancer with the primary aim of 
curing cancer
83
Immediate treatment Treatment with curative intention, typically performed within 6 months of diagnosis, without any time 
period of intended surveillance
90
Treatment shift Generic expression indicating a change in the therapeutic plan of a patient 90
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Results of the consensus initiative
Participation of experts. In total, 17 experts from the 
15 participating institutions were invited to take part in 
the first-round survey, of which 14 completed the sur-
vey and three did not respond to the invitation. These 
14 experts were invited to complete the second-round 
survey, of which 10 responded and four did not respond 
to the invitation. In total, seven of the 10 experts who 
responded to the second survey were present at the 
consensus meeting (round three). In addition, two 
experts who participated in the first-round survey but 
not in the second-round survey were present at the 
consensus meeting and participated in the semantics 
discussion. The 10 experts who participated in the 
second survey and were also present at the consensus 
meeting, and the experts who participated only in the 
first round survey and were present at the consensus 
meeting were invited for the third and final survey 
Table 1 (cont.) | Glossary of terms related to active surveillance
Term Definition % of 
agreement
Reclassification/progression
Reclassification A change in risk group as a result of re-evaluation of clinical or pathological parameters, unlikely to be 
caused by actual changes in cancer biology
80
Upgrading Change in risk group owing to an increase in Gleason grading on repeat biopsy 100
Upstaging Change in risk group owing to an increase in the extent of the disease (such as stage) based on DRE 
or imaging findings
100
Progression A broad term indicating worsening of the disease, based on an increase in grade or extent of disease 
after a follow-up period, unrelated to resampling
92
Tumour progression Clinical evidence of an increased tumour risk, based on clinical, imaging or pathological findings 75
Clinical progression New cancer related signs (such as an increase in tumour grade and/or tumour volume and/or 
clinical stage and/or PSA level) or the development or worsening of symptoms, assessed by physical 
examination (such as DRE and biopsy) and/or imaging, unrelated to resampling
92
Biochemical failure/ recurrence An increase of PSA after curative treatment above a defined threshold 92
Biochemical progression An increase of a biochemical marker over time while on AS, above a defined threshold or kinetic 
parameter
92
PSA progression (failure/
recurrence)
An increase in PSA over time more than a predefined level, calculated PSADT or PSAV, as an indicator 
of disease progression
80
Pathologic progression Change in pathological characteristics as shown by an increase of tumour grade (based on rebiopsy 
Gleason score) and/or volume (based on the number of positive cores or the maximum extent of cancer 
per core) after a follow-up period, unrelated to resampling
92
Symptomatic progression Progression of cancer such that it causes symptoms 80
MRI progression Stage progression or increase in volume or risk score of an MRI defined prostate cancer lesion, or the 
appearance of a new lesion since last MRI
100
Markers
PSA doubling time (PSADT) The time needed for PSA to double (an increase of 100%) 100
PSA velocity (PSAV) An increase in serum PSA level in a unit of time (usually per year) 100
PSA density (PSAD) Total serum PSA level divided by total prostate volume (ng/ml/cc), either measured by TRUS or MRI 100
Free PSA Serum PSA that is unbound to other proteins in the blood 100
Prostate Health Index (PHI) A PSA-based test that combines the results of three PSA measurements (standard PSA, free PSA, 
and [−2]pro-PSA) to improve accuracy for cancer
100
Prostate Cancer Antigen 3 (PCA3) A prostate specific gene, used as a urine-based biomarker, to determine risk of progression 83
Other terms
Baseline The time period during which the patient was referred to AS 80
Gleason score A grading system for prostate cancer as a method for predicting the behaviour of this disease (in terms 
of aggressiveness)
80
Grade, grading A system for classifying cancer cells based on how abnormal they appear when examined under a 
microscope, to provide information about the aggressiveness of the tumour and its tendency to spread 
in the body, according to well established criteria such as Gleason grading (ISUP)
90
Downgrading Decrease in Gleason score when comparing prostate biopsy with radical prostatectomy Gleason score 100
Stage, staging Cancer extension in the body as per the TNM staging system 90
AS, active surveillance; DRE, digital rectal exam; ISUP; International Society of Urological Pathology; PCA3, Prostate Cancer Antigen 3; PHI, Prostate Health Index; 
PSAD, PSA density; PSADT, PSA doubling time; PSAV, PSA velocity; TRUS, transrectal ultrasonography.
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(round four). In total, 12 experts were invited, all of 
whom participated (FIG. 2, TABLE 2 and Supplementary 
information S1 (table)).
Survey design and reaching a consensus. Initially, 53 
terms relating to AS were included in the first-round 
survey. Subsequently, eight new terms were added to 
this list by participants in the first round. Thus, the sec-
ond survey consisted of 61 terms. Terms were classified 
according to the following themes: background (n = 3), 
risk groups and surveillance (n = 7), cancer definitions 
(n = 6), biopsy (n = 13), treatment choice (n = 8), reclassi-
fication/progression (n = 13), markers (n = 6) and other 
AS terms (n = 5). At the end of round two, 64% (n = 39) of 
the survey items achieved consensus. The majority of the 
items and their subsequent definitions on which no con-
sensus was reached in the second survey (19 of 22) were 
discussed in more detail during the consensus meeting. 
Some items were not discussed owing to time constraints; 
these terms included localized prostate  cancer, indolent 
tumour and tumour progression. Based on the discus-
sions, some of the terms were excluded from the glossary 
(TABLE 3). Reasons for exclusion included unfamili arity 
with the concept (n = 2), insufficient evidence to deter-
mine the definition of a term (n = 1), or the experts con-
sidered them unclear and not useful in the field of AS 
(n = 9). Based on the results of the second survey and the 
consensus meeting, a third survey was designed. This 
final survey consisted of 23 items: definitions on which a 
consensus was not reached in the second survey and were 
adapted based on the input of the experts in this survey 
(n = 5); definitions on which a consensus was not reached 
in the second survey, which were discussed during the 
consensus meeting and adapted based on the experts’ 
input (n = 8); and of definitions upon which a consen-
sus was reached in the second survey, but were adapted 
slightly based on suggestions for improvement from the 
participants in this second survey (n = 10). Consensus 
was reached with respect to definitions of all these terms.
Results of the Delphi process. By the end of the Delphi 
process, formal consensus (≥70% agreement) was 
achieved on 100% of terms (n = 61). In total, consensus 
definitions were formulated for 51 terms (TABLE 1). The 
additional 10 terms were excluded from the AS glos-
sary, as all experts agreed these terms are unclear and 
unnecessary in the field of AS (TABLE 3). Of the 51 terms, 
25 definitions reached full consensus (100% agreement). 
Complete agreement was reached on definitions of key 
terms such as AS, WW, upgrading and upstaging. For 
26 items, consensus ranged from 75% to 92%. Small 
ambiguities were encountered with definitions related to 
the various risk groups that are used to stratify patients 
with prostate cancer (n = 4), cancer definitions (n = 2), 
biopsy terms (n = 2), treatment choices (n = 4), reclassi-
fication/progression (n = 9) and other AS terms (n = 5). 
Furthermore, a semantic model has been developed, 
representing an AS timeline (from prostate cancer diag-
nosis to long-term evaluation of AS), including associ-
ated terms and definitions from the glossary (FIG. 3). This 
overview includes some key terms from the glossary, but 
is not exhaustive. The first event to occur in this AS time-
line is the diagnosis of prostate cancer. Once the diagnosis 
of prostate cancer is established, further evaluation that 
incorporates known risk factors is required to determine 
appropriate treatment options. During AS, the prostate 
cancer is closely monitored over time. If repeated risk 
evaluation shows changes in the condition of the patient, 
treatment plans can be adapted accordingly.
Figure 2 | Recruitment of experts to the Delphi study. 
In total, 17 experts from the 15 participating institutions 
were invited to take part in the first-round survey, of which 
14 completed the survey and three did not respond to the 
invitation. These 14 experts were invited to complete the 
second-round survey, of which 10 responded and four did 
not respond to the invitation. In total, seven of the 10 
experts who responded to the second survey were present 
at the consensus meeting (round 3). In addition, two experts 
who participated in the first-round survey but not in the 
second-round survey were present at the consensus 
meeting and participated in the semantics discussion. The 
10 experts who participated in the second survey and were 
also present at the consensus meeting, and the experts who 
participated only in the first round survey and were present 
at the consensus meeting were invited for the third and final 
survey (round 4). In total, 12 experts were invited, all of 
whom participated making up the final expert panel. GAP3; 
Global Action Plan Prostate Cancer Active Surveillance.
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Challenges in achieving a consensus
An urgent need exists for uniform terminology regard-
ing AS in order to aid communication and collaboration 
among research groups around the world. The purpose of 
this study was to reach international consensus on defini-
tions of terms often used in AS for carefully selected men 
with localized, well-differentiated prostate cancer. Using 
a modified Delphi method in which 12 known leaders in 
the field participated, agreement has been reached on 61 
relevant terms and subsequent  definitions relating to AS 
for prostate cancer.
Several findings deserve particular attention. The 
experts encountered difficulties regarding the defini-
tions of the various risk groups used to stratify patients 
with prostate cancer, namely very-low-risk, low-risk, 
intermediate- risk and high-risk prostate cancer. The 
explanation for why these difficulties were encountered 
seems to be multifactorial. Firstly, too many doubts existed 
on the combinations of clinical  criteria — including clin-
ical and pathological characteristics — that differentiate 
the various risk groups. Many questions were raised by the 
experts, including whether only clinical stage, serum PSA 
level and Gleason score should be included; whether other 
criteria, such as PSA density and maximum percentage 
of cancer per core biopsy are also pertinent and at what 
level the cut-off values should be set. Secondly, difficul-
ties were encountered with regard to the cancer-specific 
survival rates that are associated with these risk groups. 
Thirdly, the experts had different perspectives on the 
definition of risk. For example, whether this term refers 
to the risk of metastasis or cancer-specific mortality. The 
experts concluded that, at present, the risk groups should 
not be defined, apart from general concepts, owing to the 
fact that robust data from men with clinically insignifi-
cant prostate cancer who are undergoing AS, especially 
from studies with >10 years mean follow-up duration, 
remains limited. The Movember Foundation’s GAP3 
project, which was launched in August 2014, can make a 
substantial contribution to the collection of robust data6,14. 
By combining data from existing AS databases (includ-
ing clinical, biopsy sample, imaging and biomarker data) 
from all over the world, the largest centralized prostate 
cancer AS database to date has been created, which will 
be updated annually. By subsequently analysing data from 
the majority of patients who are currently undergoing AS 
worldwide, appropriate definitions of the various risk 
groups will likely be delineated.
In addition to concerns regarding definition of the 
risk groups, intensive and complex discussion occurred 
on the distinction between the concepts of AS and WW. 
A formal consensus has been reached on the definitions 
of both management strategies, but the experts involved 
indicated that it was difficult to dichotomize surveillance. 
According to the experts, the intensity of surveillance 
gradually declines over time. An agreement seems to exist 
regarding both ends of the spectrum: protocol-based 
surveillance (that gives rise to curative treatment) at one 
end and no surveillance at the other end. However, the 
existence of a grey zone in between these strategies has 
been acknowledged (FIG. 4). This grey zone was described 
by the experts as a phase of active (regular) annual moni-
toring of serum PSA levels (no biopsies undertaken) with 
the aim of palliation when deemed necessary. Many clini-
cal questions arose, including what this strategy should be 
called in practice — the terms ‘slow surveillance’ and ‘AS 
light’ were proposed but not agreed upon — or whether 
it should simply be referred to as ‘non-protocol-based 
Table 3 | Terms excluded from the active surveillance glossary
Term Reason for exclusion % of agreement
First biopsy Unclear and not useful in the field of active surveillance 100
Second biopsy Unclear and not useful in the field of active surveillance 100
1st and 2nd biopsy Unclear and not useful in the field of active surveillance 100
Initial biopsy Unclear and not useful in the field of active surveillance 100
Repeat biopsy Unclear and not useful in the field of active surveillance 100
Serial biopsy Unclear and not useful in the field of active surveillance 100
Systematic biopsy Unclear and not useful in the field of active surveillance 100
Slow surveillance Unfamiliarity with the concept 100
Active surveillance light Unfamiliarity with the concept 100
Radiological progression Insufficient evidence as yet 100
Table 2 | Characteristics of the Delphi expert panel
Attribute Characteristic Participants (n)
Gender Male 11
Female 1
Background 
or specialty
Urologist 10
Radiation oncologist 2
Country USA 2
Canada 2
UK 2
Australia 1
France 1
Finland 1
Italy 1
Netherlands 1
Japan 1
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surveillance’. Also, the questions of what patients call 
this type of surveillance and how they perceive it, arose 
during the consensus procedure. Furthermore, how AS 
should be practiced was discussed, including aspects such 
as whether a serum PSA test should be performed every 
year or, for instance, every 5 years, and what the best 
strategy for deciding to stop the AS protocol is. Clearly, 
despite the availability of considerable consensus on 
the key terminology, continued research is necessary to 
gain a deeper understanding of these clinical aspects of 
 undertaking and practising AS.
Biopsy sampling and analysis has a role in the risk 
assessment of patients with prostate cancer who are 
eligible for AS. After initiation of an AS programme, 
most guidelines recommend use of surveillance biop-
sies to check for and identify pathological indications 
of tumour progression. Many biopsy-related terms were 
found in the literature and several more were raised by 
the experts in the survey rounds of our study, includ-
ing initial biopsy, first biopsy, second biopsy, repeat 
biopsy, serial biopsy and systematic biopsy. All experts 
agreed that the majority of these terms are unclear and 
Figure 3 | Semantic model of the active surveillance (AS) timeline (from diagnosis to long-term evaluation), 
including associated terms and definitions per stage. The first event is diagnosis of prostate cancer by biopsy sampling. 
Patients are then evaluated and stratified by the risk category of their disease: very-low-risk, low-risk, intermediate-risk, 
high-risk or clinically insignificant. A treatment choice appropriate to their risk category is then made, choices of therapy 
include AS, watchful waiting, active treatment and definitive treatment. Patients can then undergo re-evaluation 
diagnostics including a confirmatory biopsy and assessing the Gleason score of the cancer, after which a repeat risk 
evaluation can be undertaken. Based on this new risk evaluation, treatment can be adapted accordingly and patients 
enter into a long-term evaluation protocol.
Metastasis or cancer-speciﬁc 
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Watchful waiting
Management of patients with a limited 
life expectancy, in whom palliative 
treatment (without curative intent) is 
initiated if symptoms develop 
Active treatment
Treatment (such as surgery, 
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Diagnostic biopsy
The ﬁrst biopsy is positive for prostate cancer
Active surveillance
A monitoring strategy for 
patients with prostate cancer 
with the aim of avoiding or 
deferring curative treatment  
Conﬁrmatory biopsy
The prostate biopsy following a positive diagnostic biopsy (such as the ﬁrst biopsy positive for 
prostate cancer) that is intended to conﬁrm clinical insigniﬁcance of the previously diagnosed 
prostate cancer, is typically performed within 12 months after diagnosis and might target 
previously undersampled areas, according to a protocol that speciﬁes minimum standards  
Upgrading
Change in risk group 
owing to an increase 
in Gleason grading 
on repeat biopsy 
Active treatment
Treatment (such as surgery, 
radiotherapy or focal therapy) 
for prostate cancer with the 
primary aim of curing cancer 
Clinically insigniﬁcant 
disease
Prostate cancer that is, 
despite the absence of 
treatment, unlikely to 
cause symptoms, or 
metastasize (even in the 
absence of symptoms) or 
to cause mortality 
during a man’s lifetime
Low-risk disease
Prostate cancer with a 
low risk of progression 
on repeat biopsy (such as 
an increase in Gleason 
score or an increased 
number of cores positive 
for cancer) and with a 
good prognosis 
Intermediate-risk disease
Prostate cancer with a 
moderate risk of 
progression on repeat 
biopsy (such as an 
increase in Gleason score 
or an increased number of 
cores positive for cancer) 
and with a reasonable 
prognosis 
High-risk 
disease
Prostate 
cancer with a 
high risk of 
metastasis or 
cancer-speciﬁc 
death if left 
untreated 
Very-low-risk disease
Prostate cancer with a 
minimal risk of  
progression on repeat 
biopsy (such as an 
increase in Gleason score 
or an increased number 
of cores positive for 
cancer) and with very 
good prognosis 
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unnecessary in the field of AS, and, therefore, should 
not be included in the glossary (TABLE 3). The experts 
strongly advise clinicians, researchers and patients 
to limit the terms to diagnostic biopsy, confirmatory 
biopsy, protocol-based (surveillance) biopsy and non- 
protocol- based ( surveillance) biopsy to avoid  confusion 
in clinical practice.
Many definitions on which consensus was reached 
by the panel of experts incorporate references to the 
Gleason grading and scoring system. A group from 
Johns Hopkins Hospital led by Dr Epstein first pro-
posed grouping scores into five prognostic categories, 
termed Grade Groups 1–5 (REF.  15). A subsequent 
multi- institutional study of >20,000 men validated these 
Grade Groups, which resulted in its acceptance by the 
International Society of Urological Pathology, the WHO 
and the College of American Pathologists16. Importantly, 
these new grades are likely to enter mainstream prac-
tice in the near future, which will, in turn, potentially 
 influence AS terminology.
Many projects that aim to introduce standard ter-
minology in clinical practice are unsuccessful, perhaps 
because standard terminology is rarely used in clini-
cal practice7. A number of opportunities exist to con-
sider how to most effectively implement standardized 
terminology for AS into clinical practice. The aim of 
the Movember Foundation’s GAP3 initiative6,14 is to 
offer standardized, evidence-based guidelines on AS. 
The glossary of terms can be added to these guide-
lines and form the basis for a full understanding of the 
presented recommendations. Additionally, the homo-
geneous semantics should be used in presentations at 
major meetings of national and international associ-
ations, and included in papers that will be published 
in national and international scientific journals and 
specialists journals.
Strengths and weaknesses
The modified Delphi method seems to have been suc-
cessful for deriving consensus definitions. Furthermore, 
the face-to-face consensus meeting of the referee group 
enabled the in-depth exploration of the reasons for dis-
agreements on definitions. These discussions acceler-
ated the consensus process and revealed new areas of 
interest (such as the grey area between AS and WW). 
Nevertheless, this study has some limitations. As purpo-
sive sampling was used (and participants were, therefore, 
not randomly selected), representativeness cannot be 
assured. However, the whole premise behind the Delphi 
theory is that the panel members are in fact experts in 
their field, therefore, yielding results of increased accu-
racy, instead of selecting a representative sample of the 
population. Furthermore, the number of experts that par-
ticipated in this Delphi study (sample size) was relatively 
small. The number of participants could have affected 
the potential for ideas as well as the amount of data 
analysed. However, no agreement on the panel size for 
Delphi  studies exists, and neither do recommendations or 
 unequivocal definitions of small or large samples17. Many 
published Delphi studies use panels consisting of 10–100 
or more panellists17. Official consensus was obtained 
regarding all 61 definitions, but not all experts fully agreed 
with all final definitions. Consensus was considered to 
be reached if ≥70% of the experts agreed on a definition. 
In the current study, consensus varied between 75% and 
100% per item. Also, one term (radiological progression) 
has been excluded from the AS dictionary because insuf-
ficient evidence exists to include it as yet. In a system-
atic review on the use of MRI in men with low-risk or 
intermediate-risk prostate cancer who were considered 
suitable for AS, MRI was demonstrated to be useful for 
the detection of clinically significant disease at initial 
clinical assessment of men considering AS18. In addition, 
MRI might be useful for confirming the absence of any 
large anterior lesions that could have been missed during 
routine diagnosis19. However, robust, formally published 
data are needed before widespread implementation of 
MRI for this purpose18,20. Most likely, the semantics 
of AS will need to be augmented with MRI-related defi-
nitions as new evidence becomes available. During the 
course of the GAP3 project, many current patient series 
have been found to lack sufficient volume to be analysed 
appropriately. Additional funding has been committed 
by the Movember Foundation to assess the value of MRI 
within AS. In conclusion, the findings of this Delphi con-
sensus procedure represent expert opinion, rather than 
 indisputable fact, which should be kept in mind21.
Conclusions
Agreement between international experts has been 
reached on relevant terms and subsequent definitions 
regarding AS for patients with localized prostate cancer. 
This standard terminology could support multidisciplin-
ary communication, reduce the extent of variations in 
clinical practice and optimize clinical decision  making. 
International debate on all aspects of AS might be 
strengthened by an improved understanding of the 
 concept of AS.
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Figure 4 | The grey zone between active surveillance (AS) and watchful waiting 
based on expert consensus. This grey zone was described by the experts as a phase of 
active (regular) annual monitoring of serum PSA levels (no biopsies undertaken) with the 
aim of palliation when deemed necessary.
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